Login / Signup

High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in Southern Sweden.

Jonas BjörkMalin InghammarMahnaz MoghaddassiMagnus RasmussenUlf MalmqvistFredrik Kahn
Published in: Infectious diseases (London, England) (2021)
A satisfactory effectiveness of BNT162b2 after the second dose was suggested, but with possibly substantially lower effect before the second dose.
Keyphrases
  • coronavirus disease
  • sars cov
  • randomized controlled trial
  • systematic review
  • respiratory syndrome coronavirus